Targeting key proximal drivers of type 2 inflammation in disease.
New York City, United States. In Nat Rev Drug Discov, 16 Nov 2015
Rather than reducing inflammation with broad-acting immunosuppressants or narrowly targeting downstream products of the TH2 pathway, such as immunoglobulin E (IgE), efforts to target the key proximal type 2 cytokines - interleukin-4 (IL-4), IL-5 and IL-13 - represent a promising strategy to achieve therapeutic benefit across multiple diseases.
Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
London, United Kingdom. In J Allergy Clin Immunol, Sep 2015
Some patients with COPD have predominantly eosinophilic inflammation and might respond to high doses of inhaled corticosteroids and newly developed specific antieosinophil therapies, including blocking antibodies against IL-5, IL-13, IL-33, and thymic stromal lymphopoietin, as well as oral chemoattractant receptor-homologous molecule expressed on TH2 cells antagonists.